Logo image of PATH

UIPATH INC - CLASS A (PATH) Stock Fundamental Analysis

NYSE:PATH - New York Stock Exchange, Inc. - US90364P1057 - Common Stock - Currency: USD

13.43  -0.74 (-5.22%)

After market: 13.5 +0.07 (+0.52%)

Fundamental Rating

5

Overall PATH gets a fundamental rating of 5 out of 10. We evaluated PATH against 284 industry peers in the Software industry. No worries on liquidiy or solvency for PATH as it has an excellent financial health rating, but there are worries on the profitability. PATH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
PATH had a positive operating cash flow in the past year.
In the past 5 years PATH always reported negative net income.
In multiple years PATH reported negative operating cash flow during the last 5 years.
PATH Yearly Net Income VS EBIT VS OCF VS FCFPATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

PATH has a Return On Assets (-3.44%) which is comparable to the rest of the industry.
The Return On Equity of PATH (-5.29%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -3.44%
ROE -5.29%
ROIC N/A
ROA(3y)-11.83%
ROA(5y)-29.69%
ROE(3y)-16.3%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A
PATH Yearly ROA, ROE, ROICPATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 83.33%, PATH belongs to the top of the industry, outperforming 89.86% of the companies in the same industry.
In the last couple of years the Gross Margin of PATH has grown nicely.
The Profit Margin and Operating Margin are not available for PATH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y3.54%
PATH Yearly Profit, Operating, Gross MarginsPATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PATH has more shares outstanding
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PATH Yearly Shares OutstandingPATH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
PATH Yearly Total Debt VS Total AssetsPATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 4.94 indicates that PATH is not in any danger for bankruptcy at the moment.
PATH has a better Altman-Z score (4.94) than 63.41% of its industry peers.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.94
ROIC/WACCN/A
WACC13.99%
PATH Yearly LT Debt VS Equity VS FCFPATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.13 indicates that PATH has no problem at all paying its short term obligations.
PATH has a Current ratio of 3.13. This is in the better half of the industry: PATH outperforms 77.17% of its industry peers.
A Quick Ratio of 3.13 indicates that PATH has no problem at all paying its short term obligations.
PATH has a Quick ratio of 3.13. This is in the better half of the industry: PATH outperforms 77.17% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
PATH Yearly Current Assets VS Current LiabilitesPATH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.38% over the past year.
PATH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.51%.
PATH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.52% yearly.
EPS 1Y (TTM)6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)16.51%
Revenue growth 3Y29.12%
Revenue growth 5Y54.52%
Sales Q2Q%8.82%

3.2 Future

PATH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.74% yearly.
The Revenue is expected to grow by 12.48% on average over the next years. This is quite good.
EPS Next Y-9.56%
EPS Next 2Y-1.48%
EPS Next 3Y2.59%
EPS Next 5Y-0.74%
Revenue Next Year11.28%
Revenue Next 2Y11.02%
Revenue Next 3Y10.85%
Revenue Next 5Y12.48%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PATH Yearly Revenue VS EstimatesPATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
PATH Yearly EPS VS EstimatesPATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0.2 0.4 0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 26.86 indicates a quite expensive valuation of PATH.
Compared to the rest of the industry, the Price/Earnings ratio of PATH indicates a somewhat cheap valuation: PATH is cheaper than 73.55% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 29.63. PATH is around the same levels.
The Price/Forward Earnings ratio is 25.63, which means the current valuation is very expensive for PATH.
PATH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PATH is cheaper than 71.74% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.68. PATH is around the same levels.
Industry RankSector Rank
PE 26.86
Fwd PE 25.63
PATH Price Earnings VS Forward Price EarningsPATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PATH is valued a bit cheaper than the industry average as 79.35% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 23.9
EV/EBITDA N/A
PATH Per share dataPATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.48%
EPS Next 3Y2.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PATH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UIPATH INC - CLASS A

NYSE:PATH (2/21/2025, 8:04:01 PM)

After market: 13.5 +0.07 (+0.52%)

13.43

-0.74 (-5.22%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)12-05 2024-12-05/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners66.97%
Inst Owner Change5.43%
Ins Owners7.05%
Ins Owner Change0.19%
Market Cap7.38B
Analysts65.81
Price Target16.06 (19.58%)
Short Float %7.36%
Short Ratio3.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.57%
Min EPS beat(2)19.74%
Max EPS beat(2)47.41%
EPS beat(4)4
Avg EPS beat(4)28.41%
Min EPS beat(4)10.35%
Max EPS beat(4)47.41%
EPS beat(8)8
Avg EPS beat(8)105.15%
EPS beat(12)12
Avg EPS beat(12)110.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.05%
Min Revenue beat(2)0%
Max Revenue beat(2)2.1%
Revenue beat(4)3
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-1.35%
Max Revenue beat(4)3.51%
Revenue beat(8)6
Avg Revenue beat(8)2.33%
Revenue beat(12)10
Avg Revenue beat(12)2.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.35%
PT rev (3m)1.11%
EPS NQ rev (1m)17.36%
EPS NQ rev (3m)33.73%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)20.56%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 26.86
Fwd PE 25.63
P/S 5.23
P/FCF 23.9
P/OCF 23.06
P/B 4.26
P/tB 4.52
EV/EBITDA N/A
EPS(TTM)0.5
EY3.72%
EPS(NY)0.52
Fwd EY3.9%
FCF(TTM)0.56
FCFY4.18%
OCF(TTM)0.58
OCFY4.34%
SpS2.57
BVpS3.15
TBVpS2.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.44%
ROE -5.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.33%
FCFM 21.88%
ROA(3y)-11.83%
ROA(5y)-29.69%
ROE(3y)-16.3%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y3.54%
F-Score6
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 56.41%
Cap/Sales 0.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z 4.94
F-Score6
WACC13.99%
ROIC/WACCN/A
Cap/Depr(3y)82.84%
Cap/Depr(5y)103.27%
Cap/Sales(3y)1.43%
Cap/Sales(5y)2.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-9.56%
EPS Next 2Y-1.48%
EPS Next 3Y2.59%
EPS Next 5Y-0.74%
Revenue 1Y (TTM)16.51%
Revenue growth 3Y29.12%
Revenue growth 5Y54.52%
Sales Q2Q%8.82%
Revenue Next Year11.28%
Revenue Next 2Y11.02%
Revenue Next 3Y10.85%
Revenue Next 5Y12.48%
EBIT growth 1Y21.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.83%
EBIT Next 3Y22.08%
EBIT Next 5Y21.54%
FCF growth 1Y329.06%
FCF growth 3Y123.91%
FCF growth 5YN/A
OCF growth 1Y390.99%
OCF growth 3Y117.22%
OCF growth 5YN/A